Videos

Andrew Spencer, MD, MBBS, discusses the PANORAMA 3 trial data of oral panobinostat plus subcutaneous bortezomib and dexamethasone versus placebo, bortezomib, and dexamethasone.

Rajneesh Nath, MD, discusses his hypothesis on the benefits of targeted delivery of Iomab-B to the marrow in the older relapsed or refractory acute myeloid leukemia population.

Eleni Efstathiou, MD, PhD, provides background on the ARAMIS trial of darolutamide compared with placebo as treatment of patients with nonmetastatic castration-resistant prostate cancer.

Al B. Benson, MD, discusses concerns in the hepatocellular carcinoma setting for treating patients for the best outcomes.

Ecaterina Ileana Dumbrava, MD, discusses the rationale for combing BDC-1001, a HER2-targeting TLR7/8 immune-stimulating antibody conjugate with an immune checkpoint inhibitor.

Rajat Bannerji, MD, PhD, discussed key takeaways from the phase 1 study of the novel CD20xCD3 bispecific antibody, odronextamab in patients with highly refractory B-cell non-Hodgkin lymphoma.

Michael Bishop, MD, discusses the impact of chimeric antigen receptor T cell therapy across hematologic malignancies.

Nicholas Vogelzang, MD, FASCO, FACP, reacts to treatment advances in hormone-sensitive prostate cancer and provides advice to oncologists who work in community settings on best practices for managing these patients using newer treatment strategies.

An overview of the phase 3 TITAN trial in castrate-sensitive prostate cancer and implications for treating appropriate patients with apalutamide and androgen deprivation therapy.

Best practices for monitoring patients’ response to AR-targeted therapy as used to treat castrate-sensitive prostate cancer and considerations for managing patients to help prevent the emergence of castrate-resistant disease.

Second-line therapies available to treat hormone-sensitive prostate cancer and recommendations for use based on current clinical data.

The importance of risk stratifying patients with hormone-sensitive prostate cancer, and recommendations for germline and somatic testing.

Current treatment options available to treat hormone-sensitive prostate cancer in the first-line setting and factors that impact treatment selection.

Important considerations for oncologists who manage prostate cancer when establishing a treatment plan for a patient with castrate-sensitive disease.

An overview of the diagnostic work-up and treatment options offered to a 76-year-old male with castrate-sensitive prostate cancer who experiences recurrence.

Nicholas Vogelzang, MD, FASCO, FACP, comments on managing an elderly patient with hormone-sensitive prostate cancer with apalutamide and ADT based on data demonstrated by the phase 3 TITAN trial.

Kartik Konduri, MD, comments on the future of treating extensive-stage small cell lung cancer and provides advice for community oncologists treating patients with the disease.

Kartik Konduri, MD, describes the phase 2 basket trial of lurbinectedin in the treatment of extensive-stage small cell lung cancer.

Kartik Konduri, MD, discusses treatment options for extensive-stage small cell lung cancer.

Kartik Konduri, MD, evaluates the case of a 68-year-old woman with extensive-stage small cell lung cancer.

Kartik Konduri, MD, reviews the case of a 68-year-old woman with small-cell lung cancer.

Ulka N. Vaishampayan, MBBS, FAB, discusses the updated data from CheckMate 214 of nivolumab and ipilimumab versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma.

Nicholas Rohs, MD, of Mount Sinai Hospital discusses the importance of genetic testing in lung cancers that harbor KRAS and EGFR mutations.

Marcia Brose, MD, PhD discusses the key unanswered questions oncologists have for treating patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer.

Jeff Patton, MD, explains the importance of preparedness in community oncology clinics as a World Cancer Day note.

Ken Kato, MD discusses the outcomes of the phase 3 KEYNOTE-590 study on esophageal cancer.

Brendon Stiles, MD, discusses the current landscape for treating patients with metastatic lung cancer.

Final analysis of data on HER2-positive disease presented at the 2020 San Antonio Breast Cancer Symposium from experts in the field of breast oncology.

Experts in breast oncology discuss the evolving role of trastuzumab deruxtecan for metastatic HER2-positive breast cancer.

Hatem Soliman, MD, reviews statistically significant data from the PERTAIN study, presented at the 2020 San Antonio Breast Cancer Symposium.